crispr therapeutics stock CRSP Guide

A comprehensive, beginner-friendly guide to crispr therapeutics stock (CRSP) covering company background, listing details, financials, pipeline, partnerships, risks, analyst coverage and sources to...

2024-07-08 00:40:00

By Crypto Linguist

Article rating

4.2

116 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CRISPR Therapeutics AG (CRSP) — Stock

crispr therapeutics stock is the publicly traded equity of CRISPR Therapeutics AG, listed on the Nasdaq under the ticker CRSP. This article explains what crispr therapeutics stock represents, the company's core business in gene editing, how the stock is listed and traded, the primary financial and clinical drivers of value, and where to find reliable, time‑stamped market data and corporate disclosures. Readers will gain a structured reference to follow CRSP news, metrics, and events without receiving investment advice.

Company overview

CRISPR Therapeutics AG is a gene‑editing biotechnology company founded to apply the CRISPR/Cas9 technology toward therapeutic medicine. The company focuses on developing curative and durable treatments using gene editing approaches for a range of genetic diseases, hematologic disorders, oncology and in‑vivo targets. Headquartered in Basel, Switzerland, with major U.S. operations, CRISPR Therapeutics leverages CRISPR/Cas9 as its core platform to develop ex‑vivo cell therapies and in‑vivo programs.

Key executive leadership typically referenced in investor materials includes the Chief Executive Officer and the Chief Medical Officer; for the most current executive roster and biographies consult the company investor relations (IR) pages and filings. The company’s therapeutic focus areas include hemoglobinopathies (sickle cell disease and beta‑thalassemia), certain oncology cell therapies (e.g., CAR‑T variants), and in‑vivo gene‑editing candidates aimed at monogenic disorders.

This company profile explains how those development programs and regulatory events directly influence crispr therapeutics stock price movements and long‑term investor interest.

Listing and ticker information

Ticker symbol: CRSP (Nasdaq). The shorthand used in most U.S. market data services for crispr therapeutics stock is CRSP.
Exchange: Listed on the Nasdaq Stock Market as common stock. Official trade and quote feeds originate from the exchange (Nasdaq) and company IR pages for corporate actions and filings.
Share class: Common stock. Check the company’s SEC filings for details on authorized shares, preferred or other classes if applicable.
Trading hours: Regular U.S. market hours apply for CRSP (regular session and pre/post‑market sessions). Real‑time quotes and after‑hours trading data are available via market data providers and broker platforms.
Cross‑listings / ADRs: CRISPR Therapeutics AG is a U.S.-listed entity traded under CRSP; any cross‑listings or depositary receipts would be disclosed in company filings or on the IR site. For the authoritative record on share class and listing status, reference the company’s investor relations materials and Nasdaq listings information.

Market data and trading characteristics

Market data commonly used to monitor crispr therapeutics stock includes:

Current price and intraday/after‑hours quotes (sourced from Nasdaq, market data providers and broker platforms).
Market capitalization, which equals outstanding shares times current market price; market cap is time‑sensitive and should be quoted with a timestamp and data source.
Average and daily trading volume, useful for assessing liquidity.
52‑week high and low range to gauge recent volatility.
Bid/ask spreads and quoted depth, indicating immediate execution costs for market orders.
Public float and shares outstanding, often reported in filings and summarized by financial portals.

Data sources for these metrics include major financial sites and brokers (for example, company IR pages, Nasdaq, Yahoo Finance, MarketWatch, Morningstar and broker platforms). When following crispr therapeutics stock, pay attention to whether numbers are real‑time or delayed, and note the timestamp. Pre‑market and after‑hours activity can move the stock outside regular trading sessions; after‑hours liquidity tends to be thinner, which can lead to wider spreads and larger price moves.

Financial profile

Investors and analysts evaluate crispr therapeutics stock by reviewing the company’s reported financials and operational metrics. Key metrics and sections to inspect in quarterly (10‑Q) and annual (10‑K) filings or press releases include:

Revenue and revenue sources: For a development‑stage biotech, revenue may be limited and often tied to collaborations, licensing or milestone payments.
Earnings per share (EPS) and GAAP vs. non‑GAAP reconciliations.
Cash, cash equivalents and marketable securities: cash runway is critical for funding R&D and clinical programs.
Research & Development (R&D) expense and trends: R&D is typically the largest expense for a company like CRSP and is a primary driver of cash burn.
Selling, General & Administrative (SG&A) expenses.
Balance sheet items: liabilities, debt (if any), and contingent liabilities related to partnerships or legal matters.
Guidance and management commentary on expected milestones and cash runway.

Much of the prospective value of crispr therapeutics stock is tied to the pipeline and future product revenues rather than current sales; therefore, valuation hinges on the outlook for clinical programs, regulatory outcomes and partnership economics. For verified numbers, cite the company investor relations disclosures, SEC filings and the most recent quarterly report when referencing balances or metric values.

Products, pipeline and commercial progress

CRISPR Therapeutics’ development pipeline includes both commercialized therapies (where applicable) and multiple clinical‑stage programs. Major programs and their typical descriptions include:

Exa‑cel / CASGEVY (formerly known as exa‑cel): an ex‑vivo, autologous gene‑edited cell therapy developed in partnership with Vertex for the treatment of certain hemoglobinopathies (e.g., sickle cell disease and transfusion‑dependent beta‑thalassemia). Reporting on approvals, availability at authorized treatment centers (ATCs), and commercial launches directly affects crispr therapeutics stock sentiment.
CTX‑series programs (e.g., CTX112, CTX131): engineered cell therapies often aimed at oncology or hematologic indications. Each candidate has specific clinical stage designations (Phase 1/2, etc.) and enrollment milestones.
In‑vivo programs (e.g., CTX310/320, CTX211): therapeutic candidates using in‑vivo delivery of gene editing constructs for monogenic diseases. These are typically earlier stage and carry distinct regulatory and technical risk profiles.

For each candidate, investors track trial design, enrollment status, interim and pivotal data readouts, regulatory interactions, and manufacturing scale‑up plans. Company press releases, clinicaltrials.gov entries, and presentations at scientific meetings are primary sources for program updates. All pipeline status claims should be time‑stamped and sourced to company communications or filings.

Partnerships and collaborations

Strategic collaborations are central to crispr therapeutics stock fundamentals because they can provide non‑dilutive funding, development expertise and commercialization capabilities. Notable partnerships include:

Vertex Pharmaceuticals: a major collaboration for the development and commercialization of the exa‑cel/CASGEVY therapy for hemoglobinopathies. Such agreements typically outline cost sharing, milestones, royalties and co‑commercialization terms; milestone payments, royalties and license fees reported under revenue can materially affect reported financials.

Partnership agreements affect revenue recognition, milestone‑driven cash inflows, and the allocation of regulatory and commercial risk. New collaboration announcements, amendments or terminations are material events to monitor in relation to crispr therapeutics stock.

Regulatory approvals and commercialization

Regulatory milestones—such as investigational new drug (IND) clearances, biologics license applications (BLA), marketing authorizations and label decisions—are binary events that can cause substantial movement in crispr therapeutics stock. Important commercialization topics to track include:

Approvals and launch regions: where a product receives regulatory approval (e.g., U.S., EU) and the timing of those approvals.
Authorized Treatment Centers (ATCs) and launch readiness: for cell therapies, the network of capable treatment centers affects patient access and commercial rollout speed.
Early access or compassionate use programs that precede full commercialization and inform demand estimates.
Reimbursement discussions and payer coverage, which determine real‑world adoption and pricing.

For verified regulatory status and launch progress, use company press releases, regulatory authority announcements and the IR section of CRSP’s website.

Historical stock performance and corporate actions

A concise timeline of material corporate and clinical events helps contextualize past movements in crispr therapeutics stock. Common timeline items include:

Initial public offering (IPO) or U.S. listing date and ticker assignment.
Major secondary offerings or capital raises (priced offerings, convertible notes, etc.).
Clinical trial readouts, interim data releases and pivotal study outcomes that caused significant intraday or multi‑day moves.
Regulatory approvals or complete response letters (CRLs).
Strategic transactions such as licensing deals, partnerships, acquisitions or divestitures.

When recounting historical price impacts, always include a date and the primary source of the announcement (company press release, SEC filing or major financial news coverage). Corporate actions such as stock splits, reverse splits or major share issuances should be verified in filings and reflected in adjusted historical price charts if used for analysis.

Ownership, institutional holders and activist/intervention interest

Institutional ownership and major investors can influence trading dynamics for crispr therapeutics stock. Key points to consider:

Major institutional holders: large mutual funds, pension funds, or specialized biotech funds that disclose sizable positions in filings or public holdings reports.
The role of thematic funds: for example, Ark Invest’s thematic ETFs and holdings lists can influence demand if they increase or decrease allocations to companies like CRSP.
Public float and insider ownership: a higher insider ownership percentage can affect liquidity and alignment of incentives, while institutional ownership may introduce concentrated buying or selling pressure.
Activist investors: any activist interest or proxy contests would be material to shareholders and covered in filings and financial press.

Holdings can change frequently; always cite the date and source (institutional 13F filings, company proxy statements, or the reporting fund’s disclosures) when referring to current ownership data for crispr therapeutics stock.

Analyst coverage and market sentiment

Analyst reports and sell‑side coverage contribute to the market narrative around crispr therapeutics stock. Typical elements in analyst commentary include:

Consensus ratings (buy/hold/sell) and the distribution of opinions among coverage firms.
Price targets and the range of analyst estimates, which should be reported with the date of the estimate.
Thematic commentary focusing on trial timelines, probability of success, partnership economics and commercial adoption assumptions.

When summarizing analyst sentiment, include the date and the reporting outlet or analyst firm, and avoid presenting consensus as a recommendation. Analyst coverage for crispr therapeutics stock can widen or tighten depending on the company’s event calendar and the availability of clinical data.

Trading derivatives, short interest and ETFs

Derivatives and market positioning can influence short‑term moves in crispr therapeutics stock:

Options availability: an active options market allows investors to express directional views or hedge positions. Volume and open interest in listed options provide insights into hedging activity and speculative interest.
Short interest: the number and percent of float that are shorted is a gauge of bearish positioning; changes in short interest should be confirmed with timestamped exchange reports or data providers.
ETF inclusion: membership in thematic or biotech ETFs (for example, genomic or biotech funds) can create passive demand and affect liquidity. As of January 2026, thematic funds such as those managed by Ark Invest highlighted multiomics and gene editing themes that may include CRSP as a relevant holding; investors should verify ETF holdings and rebalance schedules for precise effects on crispr therapeutics stock.

All derivatives and short‑interest metrics should be quoted with source and date for accuracy.

Valuation and investment considerations

Valuing crispr therapeutics stock presents challenges common to development‑stage biotech companies:

Pipeline uncertainty: much of the company’s potential value depends on success in clinical trials and regulatory approval, which are binary and probabilistic outcomes.
Discounted cash flow (DCF) models: analysts often model potential future revenues from approved products, apply success probabilities and discount to present value—this approach requires many assumptions about pricing, patient uptake and timelines.
Relative valuation: metrics like price/sales (P/S) or enterprise value to revenue (EV/Revenue) may be used, but early‑stage biotech often has little or no revenue, making comparables less informative.
Scenario analysis: constructing best‑case, base‑case and worst‑case scenarios around trial outcomes and commercialization timing is common practice.

When discussing valuation metrics relative to crispr therapeutics stock, state assumptions clearly and cite analyst notes or modeling sources. Avoid prescriptive language or specific buy/sell guidance.

Risks

Principal risks affecting crispr therapeutics stock include:

Clinical trial risk: unexpected safety signals or lack of efficacy can halt or delay programs.
Regulatory risk: approvals are not guaranteed and may be limited in scope or face post‑approval requirements.
Commercial execution: manufacturing scale‑up and establishing treatment centers for cell therapies are operational challenges.
Competitive risk: other companies in gene editing, base editing, prime editing or alternative therapeutic modalities may reduce market opportunity.
Financial risk: cash burn and the need for additional financing can dilute existing shareholders.
Market risk: biotech sector volatility and investor sentiment swings can amplify price moves in crispr therapeutics stock.

Each risk item should be cross‑checked with company disclosures, analyst risk sections and regulatory filings.

Recent news and events

How to structure a rolling chronology for crispr therapeutics stock news:

Date and headline: include the date, succinct headline and source.
Event category: clinical data, regulatory action, earnings, partnership, capital raise, or corporate governance action.
Market impact: a neutral factual note on how the market reacted (e.g., price moved X% intraday) should be time‑stamped and sourced from market data providers.

As of January 2026, according to Ark Invest’s "Big Ideas 2026" report and related coverage, CRISPR Therapeutics was cited among companies relevant to the Multiomics theme. This thematic attention from asset managers such as Ark can influence visibility for crispr therapeutics stock in thematic ETFs and among retail and institutional investors (source: Ark Invest Big Ideas 2026 coverage reported in January 2026).

For a continuous feed of material events relevant to crispr therapeutics stock, prioritize:

Company press releases and investor relations updates.
SEC filings (8‑K for material events; 10‑Q and 10‑K for periodic reports).
Major financial news outlets and specialized biotech news sites.

All news summaries should be dated and attributed to the original source.

How to follow the stock (data sources)

Primary sources to track crispr therapeutics stock include:

Company investor relations pages for press releases, presentations and SEC‑filed documents.
SEC filings (EDGAR) for official financial reports and material event filings.
Real‑time and delayed quotes from major market data services and broker platforms; for trading and order execution consider reputable broker services and, for crypto or Web3‑adjacent custody or wallet needs, Bitget Wallet is a recommended option within this guide’s platform context.
Financial news portals (for summaries and analyst commentaries) and specialized biotech news sites for scientific and clinical context.

Note: When using third‑party data, always check the timestamp and whether the data are real‑time or delayed. For trade execution and custody, this guide suggests Bitget as an accessible trading platform and Bitget Wallet for related Web3 wallet needs in order to follow market activity and manage assets.

References and external links

Authoritative sources to cite when populating time‑sensitive figures for crispr therapeutics stock include:

CRISPR Therapeutics investor relations and press releases (company IR pages and investor presentations).
SEC filings (Form 10‑Q, 10‑K, 8‑K) for audited financials and material events.
Nasdaq listings and quote updates for official exchange data.
Financial data providers and news sites such as Yahoo Finance, MarketWatch, Morningstar, CNBC and specialized biotech outlets for market commentary and quote aggregation.
Industry news services such as BioSpace for company press and clinical program updates.

Each factual numeric claim in this article should be accompanied by a date and source when used for decision‑making. For example: "As of January 26, 2026, according to Yahoo Finance, CRSP closed at [price]."

Reporting note: this article references thematic coverage by asset managers. As of January 2026, Ark Invest’s "Big Ideas 2026" list included Multiomics as a theme and named CRISPR Therapeutics among relevant companies, which may affect visibility for crispr therapeutics stock in thematic ETFs and investor discussions (reported January 2026 by industry press covering Ark’s release).

Editorial standards: the content above is neutral and factual. It does not provide investment advice. For real‑time quotes, filings and detailed numeric figures, consult the sources listed in the References section and confirm timestamps when quoting market data related to crispr therapeutics stock.

Further exploration: to track crispr therapeutics stock in a trading or research workflow, consider creating watchlists on your preferred trading platform and subscribing to CRISPR Therapeutics’ investor alerts. For custody and wallet needs related to Web3 activity and asset management in an integrated workflow, explore Bitget Wallet and the Bitget trading platform for market access and tools.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.